Drug Information

Drug (ID: DG01765) and It's Reported Resistant Information

• Name: EGFR inhibitors
• Synonyms: EGFR inhibitors
• Drug Resistance Disease(s):
  Disease(s) with Clinically Reported Resistance for This Drug (1 diseases)
  Colorectal cancer [ICD-11: 2B91]; [1]
• Target: .; NOUNIPROTAC; [1]

Type(s) of Resistant Mechanism of This Drug

  UAPP: Unusual Activation of Pro-survival Pathway

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Colorectal cancer [ICD-11: 2B91]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Unusual Activation of Pro-survival Pathway (UAPP)

Key Molecule: GTPase Hras (HRAS) [1]

• Molecule Alteration: Missense mutation; p.G13D (c.38G>A)
• Resistant Disease: Colorectal cancer [ICD-11: 2B91.1]
• Experimental Note: Identified from the Human Clinical Data
• In Vitro Model: Colorectum; N.A.

Key Molecule: GTPase KRas (KRAS) [2]

• Molecule Alteration: IF-deletion; p.M1_E37 (c.1-11_111)
• Resistant Disease: Colorectal cancer [ICD-11: 2B91.1]
• Experimental Note: Identified from the Human Clinical Data
• Cell Pathway Regulation: EGFR signaling pathway; Activation; hsa01521
• In Vitro Model: Colorectal; N.A.

References

• Ref 1: HRAS G13D, a new mutation implicated in the resistance to anti-EGFR therapies in colorectal cancer, a case reportInt J Colorectal Dis. 2016 Jun;31(6):1245-6. doi: 10.1007/s00384-015-2448-7. Epub 2015 Nov 12.
• Ref 2: Nanofluidic Digital PCR and Extended Genotyping of RAS and BRAF for Improved Selection of Metastatic Colorectal Cancer Patients for Anti-EGFR TherapiesMol Cancer Ther. 2016 May;15(5):1106-12. doi: 10.1158/1535-7163.MCT-15-0820. Epub 2016 Apr 1.